Table 3.
Summary of receipt of GCC by racial groups
| Criteria | Hispanic, N = 145 (%) | NHB, N = 153 (%) | NHW, N = 1,911 (%) | P value |
|---|---|---|---|---|
| Nodal retrieval | | | 0.3 | |
| GCC (≥12 lymph nodes) | 139 (95.9) | 151 (98.7) | 1,857 (97.2) | |
| Non-GCC (<12 lymph nodes) | 6 (4.1) | 2 (1.3) | 54 (2.8) | |
| Adjuvant chemotherapya | | | >0.9 | |
| GCC | 138 (95.2) | 147 (96.1) | 1,829 (95.7) | |
| Non-GCC | 7 (4.8) | 6 (3.9) | 82 (4.3) | |
| Overall | | | 0.4 | |
| GCC | 132 (91) | 145 (94.8) | 1,784 (93.4) | |
| Non-GCC | 13 (9) | 8 (5.2) | 127 (6.6) | |
a
GCC for adjuvant chemotherapy was defined as (i) adjuvant chemotherapy for stage III, (ii) adjuvant chemotherapy for stage II with high-risk features (<12 lymph nodes retrieved and evidence of lymphovascular invasion), and (iii) no adjuvant chemotherapy for stage I and low-risk stage II. Non-GCC was defined as (i) no adjuvant chemotherapy for stage III and stage II with high-risk features or (ii) adjuvant chemotherapy for stage I and low-risk stage II disease.